Market research
3O8.F Omeros Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- 11.52
- Analyst target
- 34.63
- Dividend yield
- Not available
- Beta
- 2.54
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6821431029
- Market cap
- 1B
- P/E ratio
- 11.52
- Analyst target
- 34.63
- Dividend yield
- Not available
- Beta
- 2.54
About
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 3O8.F discussion.
5 years, 4 months ago
Omeros Corporation is currently in a long term downtrend where the price is trading 7.0% below its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Omeros Corporation's total revenue sank by 68.2% to $11M since the same quarter in the previous year.
Its net income has dropped by 27.5% to $-37M since the same quarter in the previous year.
Finally, its free cash flow grew by 20.1% to $-18M since the same quarter in the previous year.
Based on the above factors, Omeros Corporation gets an overall score of 2/5.